[HTML][HTML] Experimental and clinical treatment of Chagas disease: a review

PAS Junior, I Molina, SMF Murta… - The American journal …, 2017 - ncbi.nlm.nih.gov
Chagas disease (CD) is caused by the protozoan parasite Trypanosoma cruzi that infects a
broad range of triatomines and mammalian species, including man. It afflicts 8 million …

Nanopharmaceuticals as a solution to neglected diseases: Is it possible?

GA Islan, M Durán, ML Cacicedo, G Nakazato… - Acta tropica, 2017 - Elsevier
The study of neglected diseases has not received much attention, especially from public and
private institutions over the last years, in terms of strong support for developing treatment for …

Congenital transmission of Chagas disease: a clinical approach

I Oliveira, F Torrico, J Muñoz… - Expert review of anti …, 2010 - Taylor & Francis
Chagas disease is caused by the protozoan Trypanosoma cruzi and is an endemic zoonosis
in the American continent. Thanks to the successful implementation of national programs for …

Synthesis of Silver Nanoparticle Employing Corn Cob Xylan as a Reducing Agent with Anti-Trypanosoma cruzi Activity

TK Brito, RL Silva Viana… - International journal …, 2020 - Taylor & Francis
Background Chagas disease, also known as American Trypanosomiasis, is caused by the
protozoan Trypanosoma cruzi. It is occurring in Americas, including USA and Canada, and …

First century of chagas' disease: An overview on novel approaches to nifurtimox and benznidazole delivery systems

CJ Salomon - Journal of Pharmaceutical Sciences, 2012 - Elsevier
Hundred years after the discovery of Chagas' disease, there is a lack of effective treatment to
control this neglected disease caused by the parasite Trypanosoma cruzi. The transmission …

Therapy, diagnosis and prognosis of chronic Chagas disease: insight gained in Argentina

S Sosa-Estani, R Viotti, EL Segura - Memórias do Instituto Oswaldo …, 2009 - SciELO Brasil
The purpose of this review is to describe research findings regarding chronic Chagas
disease in Argentina that have changed the standards of care for patients with Trypanosoma …

Clinical trials for Chagas disease: etiological and pathophysiological treatment

BMS Gonzaga, RR Ferreira, LL Coelho… - Frontiers in …, 2023 - frontiersin.org
Chagas disease (CD) is caused by the flagellate protozoan Trypanosoma cruzi. It is
endemic in Latin America. Nowadays around 6 million people are affected worldwide, and …

Development of novel formulations for Chagas' disease: optimization of benznidazole chitosan microparticles based on artificial neural networks

D Leonardi, CJ Salomón, MC Lamas… - International journal of …, 2009 - Elsevier
Benznidazole (BZL) is one of the two therapeutic agents used for the treatment of Chagas'
disease. However, the use of BZL in most pharmaceutical preparations and research …

Development and characterization of benznidazole nano-and microparticles: a new tool for pediatric treatment of Chagas disease?

KP Seremeta, EC Arrúa, NB Okulik… - Colloids and Surfaces B …, 2019 - Elsevier
Benznidazole (BNZ) is the drug of choice for the treatment of Chagas disease in many
countries. However, its low water solubility produces low and/or variable oral bioavailability …

[HTML][HTML] Nanocarriers for effective delivery of benznidazole and nifurtimox in the treatment of chagas disease: A review

EC Arrúa, KP Seremeta, GR Bedogni, NB Okulik… - Acta tropica, 2019 - Elsevier
Neglected tropical diseases (NTDs) constitute a group of infectious diseases prevalent in
countries with tropical and subtropical climate that affect the poorest individuals and produce …